Ritter Pharmaceuticals Inc (NASDAQ:RTTR) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $0.71 and last traded at $0.80, with a volume of 2267 shares changing hands. The stock had previously closed at $0.83.
RTTR has been the subject of a number of analyst reports. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Ritter Pharmaceuticals in a report on Wednesday, August 15th. Finally, ValuEngine upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd.
The firm has a market cap of $4.76 million, a P/E ratio of -0.15 and a beta of 1.21.
About Ritter Pharmaceuticals (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
See Also: Why do companies engage in swaps?
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.